Title: Risk Factors and Management of Gastrointestinal Bleeding in Patients With or Without
Antiplatelet and Anticoagulation therapy: a Multicenter Real-world Prospective Study
Version: 1 Date: 28 Dec 2023
Reviewer's report:
Authors performed this study to investigate the association between previous antiplatelet or
anticoagulant durg usage and outcomes in GIB patients.
The study has valuable points but I recommend some changes.
Introduction:
please specify the % of GIB associated associated with antiplatelet and anticoagulant uses
Also, information on the previous studies on GIB related to antiplatelt and naticoagulant is
needed
Methods:
GIB usually occurs in elderly populations. However, did you include pregant or breast feeding
women in the study?
Please specify medicatoins classified as anticoagulation and antiplatlets.
Comorbidity may also contribute significnatly to GIB incidences (ex. GI disorders - hepatic
disorders, GERD, PUD, and other cardiovascular disorders). Please add variables related to
comorobidities. If it is not possible, please add following information in the limitation.
The baseline characteristics seem different. How did you adjusted these difference throughout
the study?
Title: Risk Factors and Management of Gastrointestinal Bleeding in Patients With or Without
Antiplatelet and Anticoagulation therapy: a Multicenter Real-world Prospective Study
Version: 1 Date: 28 Dec 2023
Reviewer's report:
Authors performed this study to investigate the association between previous antiplatelet or
anticoagulant durg usage and outcomes in GIB patients.
The study has valuable points but I recommend some changes.
Introduction:
please specify the % of GIB associated associated with antiplatelet and anticoagulant uses
Also, information on the previous studies on GIB related to antiplatelt and naticoagulant is
needed
Methods:
GIB usually occurs in elderly populations. However, did you include pregant or breast feeding
women in the study?
Please specify medicatoins classified as anticoagulation and antiplatlets.
Comorbidity may also contribute significnatly to GIB incidences (ex. GI disorders - hepatic
disorders, GERD, PUD, and other cardiovascular disorders). Please add variables related to
comorobidities. If it is not possible, please add following information in the limitation.
The baseline characteristics seem different. How did you adjusted these difference throughout
the study?
Please review this paper.
user
Title: Risk Factors and Management of Gastrointestinal Bleeding in Patients With or Without
Antiplatelet and Anticoagulation therapy: a Multicenter Real-world Prospective Study
Version: 1 Date: 28 Dec 2023
Reviewer's report:
Authors performed this study to investigate the association between previous antiplatelet or
anticoagulant durg usage and outcomes in GIB patients.
The study has valuable points but I recommend some changes.
Introduction:
please specify the % of GIB associated associated with antiplatelet and anticoagulant uses
Also, information on the previous studies on GIB related to antiplatelt and naticoagulant is
needed
Methods:
GIB usually occurs in elderly populations. However, did you include pregant or breast feeding
women in the study?
Please specify medicatoins classified as anticoagulation and antiplatlets.
Comorbidity may also contribute significnatly to GIB incidences (ex. GI disorders - hepatic
disorders, GERD, PUD, and other cardiovascular disorders). Please add variables related to
comorobidities. If it is not possible, please add following information in the limitation.
The baseline characteristics seem different. How did you adjusted these difference throughout
the study?
assistant